Form 13-F position report

ENANTA PHARMACEUTICALS INC

Reported by D E Shaw & Co Inc

ENTA CUSIP 29251M106 Manager CIK 0001009207

Reported 282,276 shares, down 101,044 (26.4%) from the prior quarter.

Reported value 0.9%; share count -26.4% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 282,276 Quarter-end amount reported
Reported value $2,134,006 Fair value at quarter end
Consecutive quarters held 36 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 587000
2021-12-31 1833000
2022-03-31 435000
2022-06-30 224000
2022-09-30 246000
2022-12-31 220551
2023-03-31 0
2023-06-30 1124549
2023-09-30 4032951
2023-12-31 6005161
2024-03-31 9956495
2024-06-30 6928328
2024-09-30 5194214
2024-12-31 2424166
2025-03-31 2115926
2025-06-30 2134006
2025-09-30 2702156
2025-12-31 2644850
2026-03-31 895265
2026-06-30 503579

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ENANTA PHARMACEUTICALS INC held by D E Shaw & Co Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 34,539 -36,345 (-51.3%) < 0.01% $503,579 2026-08-14
Q1 2026 Reduced 70,884 -96,830 (-57.7%) < 0.01% $895,265 2026-05-15
Q4 2025 Reduced 167,714 -58,030 (-25.7%) < 0.01% $2,644,850 2026-02-17
Q3 2025 Reduced 225,744 -56,532 (-20.0%) < 0.01% $2,702,156 2025-11-14
Q2 2025 Reduced 282,276 -101,044 (-26.4%) < 0.01% $2,134,006 2025-08-14
Q1 2025 Reduced 383,320 -38,274 (-9.1%) < 0.01% $2,115,926 2025-05-15
Q4 2024 Reduced 421,594 -79,778 (-15.9%) < 0.01% $2,424,166 2025-02-14
Q3 2024 Reduced 501,372 -32,809 (-6.1%) < 0.01% $5,194,214 2024-11-14
Q2 2024 Reduced 534,181 -36,065 (-6.3%) < 0.01% $6,928,328 2024-08-14
Q1 2024 Reduced 570,246 -67,922 (-10.6%) < 0.01% $9,956,495 2024-05-15
Q4 2023 Added 638,168 +277,116 (76.8%) < 0.01% $6,005,161 2024-02-14
Q3 2023 Added 361,052 +308,503 (587.1%) < 0.01% $4,032,951 2023-11-14
Q2 2023 New 52,549 +52,549 (0.0%) < 0.01% $1,124,549 2023-08-14
Q1 2023 Reduced 0 -4,741 (-100.0%) 0 $0 2023-05-15
Q4 2022 Unchanged 4,741 0 (0.0%) < 0.01% $220,551 2023-02-14
Q3 2022 Unchanged 4,741 0 (0.0%) < 0.01% $246,000 2022-11-14
Q2 2022 Reduced 4,741 -1,364 (-22.3%) < 0.01% $224,000 2022-08-15
Q1 2022 Reduced 6,105 -18,403 (-75.1%) < 0.01% $435,000 2022-05-16
Q4 2021 Added 24,508 +14,172 (137.1%) < 0.01% $1,833,000 2022-02-14
Q3 2021 Reduced 10,336 -14,404 (-58.2%) < 0.01% $587,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

126 managers reported ENANTA PHARMACEUTICALS INC for Q2 2025.

Managers reporting ENANTA PHARMACEUTICALS INC in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FARALLON CAPITAL MANAGEMENT LLC Unchanged 2,122,262 0 0.07% $16,044,301 32 qtrs
Krensavage Asset Management LLC Reduced 2,114,444 -2,142 8.46% $15,985,000 42 qtrs
VANGUARD GROUP INC Reduced 1,976,672 -30,761 < 0.01% $14,943,640 49 qtrs
BlackRock Inc Reduced 1,846,905 -171,764 < 0.01% $13,962,601 4 qtrs
MILLENNIUM MANAGEMENT LLC Added 1,458,593 +111,661 < 0.01% $11,026,963 37 qtrs
ACADIAN ASSET MANAGEMENT LLC Unchanged 867,037 0 0.01% $6,551,000 9 qtrs
MARSHALL WACE LLP Added 857,412 +6,522 < 0.01% $6,482,034 8 qtrs
Stonepine Capital Management LLC Added 604,066 +13,324 4.48% $4,566,739 3 qtrs
JANUS HENDERSON GROUP PLC New 523,743 +523,743 < 0.01% $3,956,878 1 qtr
GEODE CAPITAL MANAGEMENT LLC Reduced 485,797 -8,408 < 0.01% $3,673,147 49 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
273,647
Shared
0
None
8,629

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.